Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 298, Issue 1-2, Pages 84-88Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2008.09.015
Keywords
FSH receptor; Pharmacoperone; Peptidomimetic; Small molecule; GPCR; Receptor; Therapeutics
Categories
Funding
- NIH [HD-19899, TW/HD-00668, RR-00163, HD-18185, HD-18407]
Ask authors/readers for more resources
A thienopyr(im)idine (Org41841) activates the luteinizing hormone (LH) receptor but does not compete with the natural ligand binding site and does not show agonistic action on the follicle-stimulating hormone receptor (hFSHR) at sub-millimolar concentrations. When this drug is preincubated at sub-micromolar concentrations with host cells expressing the hFSHR, and then washed out, binding analysis and assessment of receptor-effector coupling show that it increases plasma membrane expression of the hFSHR. Real-time PCR shows that this effect did not result from increased hFSHR mRNA accumulation. It is possible that Org41841 behaves as a pharmacoperone, a drug which increases the percentage of newly synthesized receptor routing to the membrane. Like pharmacoperones for other receptors, this drug was able to rescue a particular mutant hFSHR (A(189)V) associated with misrouting and endoplasmic reticulum retention, although other mutants could not be rescued. This is potentially the first member of the pharmacoperone drug class which binds at a site that is distinctive from the ligand binding site. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available